Previous Close | 6.15 |
Open | 6.15 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 50.00 |
Expire Date | 2024-06-28 |
Day's Range | 6.15 - 6.15 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
PRINCETON, N.J., June 03, 2024--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations...
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.